The $165 price level has emerged as a closely watched target for CELC because it represents the median 12-month analyst price target among the 12 analysts covering the stock, according to data from MarketWatch and StockAnalysis. With estimates ranging from Leerink Partners' $147 on the low end to Craig-Hallum's $178 on the high end, the $165 consensus sits squarely in the middle — a figure reiterated by firms including Guggenheim, LifeSci Capital, and Stifel Nicolaus in recent weeks. Given that the stock last traded at roughly half that level, the question of whether Celcuity can reclaim ground toward triple-digit territory has become one of the most debated topics among biotechnology investors.
Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on developing targeted therapies for solid tumors. Its lead drug candidate, gedatolisib, is a pan-PI3K and mTOR inhibitor licensed from PFE (Pfizer) that simultaneously targets Class I PI3K isoforms and both mTORC1 and mTORC2 complexes. The company's most advanced program evaluates gedatolisib in patients with HR+/HER2- advanced or metastatic breast cancer through the pivotal Phase III VIKTORIA-1 trial. Celcuity is also exploring the drug in metastatic castration-resistant prostate cancer (mCRPC). As a pre-revenue company, Celcuity currently generates no product sales and funds operations entirely through equity and debt financing.
Celcuity's stock chart tells a dramatic story. Over the trailing 52 weeks, shares have surged more than 490%, catapulting from approximately $14 to a 52-week high of $151.02. Yet more recently, the stock has surrendered significant ground, falling to $82.27 — a decline exceeding 45% from its peak. The pullback has pushed CELC below both its 50-day moving average near $105 and its 200-day moving average around $103, placing the stock in a technically weakened position. The current market capitalization stands at roughly $4.03 billion, reflecting a valuation built almost entirely on the promise of gedatolisib's future commercial potential rather than any current revenue.
The bull case for Celcuity reaching $165 rests primarily on gedatolisib's clinical profile. In July 2025, the company announced positive topline results from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, a milestone that prompted several analysts to raise price targets dramatically. The company has indicated plans to submit a New Drug Application (NDA) for gedatolisib in the PIK3CA wild-type indication, and full data presentation at a major medical meeting is expected to provide further clarity on the drug's efficacy and safety profile in key subgroups.
Beyond the wild-type opportunity, the PIK3CA mutant cohort readout represents an additional catalyst that, if positive, could roughly double gedatolisib's addressable patient population. Analysts at Needham have previously estimated combined peak sales potential exceeding $3.6 billion across both indications. On the financial side, Celcuity ended a recent quarter with a pro forma cash position of approximately $455 million following a financing, providing a runway expected to fund operations through 2027 — past several critical inflection points.
The path to $165 is far from guaranteed. First, Celcuity remains entirely pre-revenue and deeply unprofitable, with trailing twelve-month net income of approximately negative $193 million and EPS of -$3.89. The company will likely require additional capital before reaching commercialization, introducing dilution risk for existing shareholders. Second, the competitive landscape in HR+/HER2- breast cancer is intensifying, with approved therapies from NVS (Novartis), AZN (AstraZeneca), and others already well-established in the treatment paradigm.
Third, the PIK3CA mutant cohort readout — while potentially a powerful upside catalyst — also represents a binary risk event. Negative or equivocal data could materially undermine the investment thesis. Finally, the stock's dramatic volatility and recent breakdown below key moving averages suggest technical headwinds that may take time to resolve, even if fundamentals continue to improve.
Wall Street remains overwhelmingly constructive on CELC. All 12 analysts tracked by major data aggregators maintain either Buy or Strong Buy ratings, with zero Hold or Sell recommendations as of July 2026. The consensus price target of approximately $163.45 implies upside of roughly 98% from the July 27 closing price. Recent actions include Craig-Hallum raising its target to $178, Stifel Nicolaus maintaining at $175, and Guggenheim and LifeSci Capital each reiterating $165 targets in July 2026. Leerink Partners, at the lower end, maintains a $147 target. The uniformity of bullish sentiment — while supportive — also warrants caution: consensus optimism in biotechnology can reverse quickly if key catalysts disappoint.
From a technical perspective, CELC faces multiple hurdles before any sustained move toward $165 becomes viable. The 200-day moving average near $103 and the 50-day moving average around $105 represent the first significant resistance zone the stock must reclaim. Above that, the psychologically important $100 level and the prior breakdown zone near $115–$117 mark additional supply areas. On the downside, the recent low near $81–$82 serves as immediate support, with the 52-week low at $13.59 representing the ultimate risk floor. The 52-week high of $151.02 remains the most important reference point — any credible path to $165 almost certainly requires first recapturing that prior peak.
Navigating a volatile stock like Celcuity requires timely, data-driven decision-making. AI Daily Buy/Sell Signals from Tickeron offer traders an automated way to monitor thousands of stocks and ETFs using artificial intelligence. The system continuously scans changing market conditions, technical patterns, and AI-driven analytics to generate actionable Buy, Sell, or Hold signals. For investors tracking positions in clinical-stage biotechnology companies — where sentiment can shift rapidly on clinical data and regulatory news — these AI-generated signals can help identify emerging opportunities and flag deteriorating trends more efficiently than manual screening alone. Traders looking to stay ahead of market moves may find value in incorporating this tool into their daily research routine.
Can Celcuity reach $165? The question ultimately hinges on execution. The analyst consensus and the fundamental opportunity around gedatolisib provide a coherent roadmap: if the company delivers positive PIK3CA mutant data, submits a successful NDA, and progresses toward commercialization, a return toward prior highs and beyond is mathematically possible. The stock has already demonstrated its capacity for explosive moves, having rallied more than tenfold from its 2025 lows. However, the realistic path to $165 demands near-flawless execution across clinical, regulatory, and commercial fronts — a tall order for any pre-revenue biotechnology company. Investors should monitor the upcoming earnings report scheduled for mid-August 2026, the PIK3CA mutant data readout, and any NDA submission updates as the most important signposts on the road ahead. The gap between $82 and $165 is wide, but in biotechnology, wide gaps have been closed before when the science works.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.
| Ticker / NAME | Correlation To CELC | 1D Price Change % | ||
|---|---|---|---|---|
| CELC | 100% | -5.95% | ||
| IMA - CELC | 76% Closely correlated | -2.00% | ||
| SLXN - CELC | 50% Loosely correlated | +1.30% | ||
| ABOS - CELC | 44% Loosely correlated | +1.59% | ||
| GLSI - CELC | 39% Loosely correlated | -3.19% | ||
| HRTX - CELC | 38% Loosely correlated | -1.91% | ||
More | ||||